AUSTRALIAN JOURNAL OF BIOMEDICAL RESEARCH
Review Article
Jul 15, 2026 5 2

CRISPR-Cas9 in Human Health: A Scoping Review of Therapeutic Applications, Safety Challenges, and Ethical Frameworks

Muhydeen Damilola Badru 1,
Verity Ghansah 2,
Ifeoluwa Oyinkansola Adesanya 3,
Joseph David 4,
Nkemdilim Clairelouise Okechukwu 5,
Daniel Obinna Eke 6 *
1 Department of Haematology and Immunology, Obafemi Awolowo University, Ile-Ife, Nigeria 2 Department of Biology, New Mexico Institute of Mining and Technology, Socorro, NM, USA3 Department of Medicine and Surgery, Olabisi Onabanjo University, Ago-iwoye, Ogun state, Nigeria 4 Department of Microbiology, Abubakar Tafawa Balewa University, Bauchi State, Nigeria 5 Department of Medical Microbiology, Enugu State University Teaching Hospital, Parklane, Enugu, Nigeria6 Department of Nursing, Myrtle E. and Earl E. Walker College of Health Professions, Maryville University of St. Louis, St. Louis, MO, USA* Corresponding Author
Australian Journal of Biomedical Research, 2(3), 2026, aubm024, https://doi.org/10.63946/aubiomed/18967
Publication date: Jul 15, 2026
Full Text (PDF)

ABSTRACT

Background: CRISPR-Cas9 has revolutionized genome editing by providing an efficient, versatile, and comparatively accessible platform for targeted genetic modification. Its rapid progression from laboratory innovation to clinical application has generated substantial interest across multiple therapeutic domains, while simultaneously raising significant safety, ethical, and regulatory concerns.
Objective: This scoping review aimed to comprehensively map current evidence regarding the therapeutic applications, safety challenges, and ethical frameworks associated with CRISPR-Cas9 in human health.
Methods: A scoping review methodology guided by the Arksey and O’Malley framework and PRISMA-ScR guidelines was employed. Comprehensive searches were conducted across PubMed, Dimensions, and Embase for peer-reviewed English-language studies published between 2015 and 2026. Eligible studies focused on CRISPR-Cas9 applications in human health, including therapeutic interventions, safety evaluations, ethical analyses, and regulatory considerations. A total of 32 studies met the inclusion criteria and underwent thematic synthesis.
Results: CRISPR-Cas9 demonstrated substantial therapeutic promise across hematologic disorders, metabolic diseases, ophthalmologic conditions, oncology, immunotherapy, and rare genetic disorders. The most clinically advanced applications were observed in sickle cell disease, β-thalassemia, hereditary transthyretin amyloidosis, and hereditary angioedema, where clinical trials showed durable and potentially curative outcomes. However, major barriers remain, including off-target effects, genomic instability, delivery inefficiencies, immunogenicity, and limited long-term safety data. Ethical and regulatory concerns were prominent, particularly regarding germline editing, health equity, global governance, and accessibility.
Conclusion: CRISPR-Cas9 has demonstrated considerable clinical potential across a range of therapeutic applications, particularly for selected monogenic disorders in which the strongest clinical evidence is currently available. Although important advances have been achieved, broader clinical implementation will require continued improvements in editing precision, long-term safety evaluation, delivery technologies, ethical oversight, equitable access, and harmonized regulatory frameworks.
 

KEYWORDS

CRISPR-Cas9 Genome Editing Precision Medicine Therapeutic Applications Ethical Challenges

CITATION (Vancouver)

Badru MD, Ghansah V, Adesanya IO, David J, Okechukwu NC, Eke DO. CRISPR-Cas9 in Human Health: A Scoping Review of Therapeutic Applications, Safety Challenges, and Ethical Frameworks. Australian Journal of Biomedical Research. 2026;2(3):aubm024. https://doi.org/10.63946/aubiomed/18967
APA
Badru, M. D., Ghansah, V., Adesanya, I. O., David, J., Okechukwu, N. C., & Eke, D. O. (2026). CRISPR-Cas9 in Human Health: A Scoping Review of Therapeutic Applications, Safety Challenges, and Ethical Frameworks. Australian Journal of Biomedical Research, 2(3), aubm024. https://doi.org/10.63946/aubiomed/18967
Harvard
Badru, M. D., Ghansah, V., Adesanya, I. O., David, J., Okechukwu, N. C., and Eke, D. O. (2026). CRISPR-Cas9 in Human Health: A Scoping Review of Therapeutic Applications, Safety Challenges, and Ethical Frameworks. Australian Journal of Biomedical Research, 2(3), aubm024. https://doi.org/10.63946/aubiomed/18967
AMA
Badru MD, Ghansah V, Adesanya IO, David J, Okechukwu NC, Eke DO. CRISPR-Cas9 in Human Health: A Scoping Review of Therapeutic Applications, Safety Challenges, and Ethical Frameworks. Australian Journal of Biomedical Research. 2026;2(3), aubm024. https://doi.org/10.63946/aubiomed/18967
Chicago
Badru, Muhydeen Damilola, Verity Ghansah, Ifeoluwa Oyinkansola Adesanya, Joseph David, Nkemdilim Clairelouise Okechukwu, and Daniel Obinna Eke. "CRISPR-Cas9 in Human Health: A Scoping Review of Therapeutic Applications, Safety Challenges, and Ethical Frameworks". Australian Journal of Biomedical Research 2026 2 no. 3 (2026): aubm024. https://doi.org/10.63946/aubiomed/18967
MLA
Badru, Muhydeen Damilola et al. "CRISPR-Cas9 in Human Health: A Scoping Review of Therapeutic Applications, Safety Challenges, and Ethical Frameworks". Australian Journal of Biomedical Research, vol. 2, no. 3, 2026, aubm024. https://doi.org/10.63946/aubiomed/18967

SUPPLEMENTARY FILES

Supplementary File

REFERENCES

  1. Ahmed, R., Alghamdi, W. N., Alharbi, F. R., Alatawi, H. D., Alenezi, K. M., Alanazi, T. F., & Elsherbiny, N. M. (2025). CRISPR/Cas9 system as a promising therapy in thalassemia and sickle cell disease: A systematic review of clinical trials. Molecular Biotechnology, 68(1), 23–32. https://doi.org/10.1007/s12033-025-01368-x
  2. Alex, R., & Winkler, D. A. (2024). Ethical frameworks for genome and epigenome editing in modern medicine. Bioethics Review, 38(2), 145–162.
  3. Aljabali, A. A. A., El-Tanani, M., & Tambuwala, M. M. (2024). Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology, 92, Article 105338. https://doi.org/10.1016/j.jddst.2024.105338
  4. Amiri, M., Moaveni, A. K., Majidi Zolbin, M., Shademan, B., & Nourazarian, A. (2024). Optimizing cancer treatment: The synergistic potential of CAR-T cell therapy and CRISPR/Cas9. Frontiers in Immunology, 15, Article 1462697. https://doi.org/10.3389/fimmu.2024.1462697
  5. Arksey, H., & O’Malley, L. (2005). Scoping studies: Towards a methodological framework. International Journal of Social Research Methodology, 8(1), 19–32. https://doi.org/10.1080/1364557032000119616
  6. Cohn, D. M., et al. (2025). In vivo CRISPR-Cas9-mediated KLKB1 gene editing for hereditary angioedema. New England Journal of Medicine, 392(4), 321–333.
  7. Davis, D. J., & Yeddula, S. G. R. (2024). CRISPR advancements for human health. Missouri Medicine, 121(2), 170–176.
  8. Dickson, B. E. (2026). Hemodynamic instability following major surgery: Early nursing assessment and intervention outcomes: A systematic review. Journal of Medicine and Health Research, 11(1). https://doi.org/10.56557/jomahr/2026/v11i110362
  9. Dickson, B. E., Gab-Obinna, C., Eke, D. O., & Akinlotan, S. O. (2026). Preoperative anxiety management: The effectiveness of nurse-led educational interventions on surgical outcomes: A narrative review. Asian Journal of Research in Nursing and Health, 9(1). https://doi.org/10.9734/ajrnh/2026/v9i1308
  10. Duran, J. M., et al. (2026). Hematopoietic stem-cell CRISPR correction restores immune function in Artemis immunodeficiency. Nature Medicine, 32(1), 44–56.
  11. Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y. S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2024). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 390(9), 805–817.
  12. Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 385(6), 493–502.https://doi.org/10.1056/NEJMoa2107454
  13. Gillmore, J. D., et al. (2025). Long-term safety and efficacy of CRISPR-Cas9 therapy in hereditary transthyretin amyloidosis with polyneuropathy. Nature Medicine, 31(3), 410–420.
  14. Guan, Y., Ma, Y., Li, Q., Sun, Z., Ma, L., Wu, L., Wang, L., Zeng, L., Shao, Y., Chen, Y., et al. (2016). CRISPR/Cas9-mediated somatic correction of hemophilia B in mice. EMBO Molecular Medicine, 8(5), 477–488. https://doi.org/10.15252/emmm.201506039
  15. He, Z. Y., Zhang, Y. G., Yang, Y. H., Ma, C. C., Wang, P., Du, W., Li, L., Xiang, R., Song, X. R., Zhao, X., et al. (2018). In vivo ovarian cancer gene therapy using CRISPR-Cas9. Human Gene Therapy, 29(2), 223–233. https://doi.org/10.1089/hum.2017.209
  16. Humbert, O., Samuelson, C., & Kiem, H. P. (2021). CRISPR/Cas9 for the treatment of haematological diseases: A journey from bacteria to the bedside. British Journal of Haematology, 192(1), 33–49. https://doi.org/10.1111/bjh.16807
  17. Iyer, S. P., Sica, R. A., Ho, P. J., Prica, A., Zain, J., Foss, F. M., Hu, B., Beitinjaneh, A., Weng, W. K., Kim, Y. H., et al. (2025). Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in relapsed or refractory T-cell malignancies (COBALT-LYM): A single-arm, open-label, phase 1 dose-escalation study. The Lancet Oncology, 26(1), 110–122. https://doi.org/10.1016/S1470-2045(24)00508-4
  18. Jo, Y. I., Suresh, B., Kim, H., & Ramakrishna, S. (2015). CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1856(2), 234–243. https://doi.org/10.1016/j.bbcan.2015.09.003
  19. Kalter, N., Fuster-García, C., Silva, A., Ronco-Díaz, V., Roncelli, S., Turchiano, G., Gorodkin, J., Cathomen, T., Benabdellah, K., Lee, C., & Hendel, A. (2025). Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges. Molecular Therapy: Nucleic Acids, 36(3), Article 102636. https://doi.org/10.1016/j.omtn.2025.102636
  20. Karimi, M. A., Paryan, M., Behrouzian Fard, G., Sadeghian, H., Zarrinfar, H., & Hosseini Bafghi, M. (2026). Challenges and opportunities in the application of CRISPR-Cas9: A review on genomic editing and therapeutic potentials. Medical Principles and Practice, 35(1), 1–17. https://doi.org/10.1159/000547334
  21. Khare, P., Mandal, S., Verma, A. K., Parashar, D., Jadhav, K., & Gupta, S. (2023). CRISPR: The Janus god of modern science. In the CRISPR-Cas system in translational biotechnology (pp. 23–56). Elsevier. https://doi.org/10.1016/B978-0-323-91808-4.00006-7
  22. Kolanu, N. D. (2024). CRISPR-Cas9 gene editing: Curing genetic diseases by inherited epigenetic modifications. Global Medical Genetics, 11(1), 113–122. https://doi.org/10.1055/s-0044-1785234
  23. Laffin, M., et al. (2025). Phase 1 study of in vivo CRISPR-Cas9 targeting ANGPTL3 for dyslipidemia. New England Journal of Medicine, 392(7), 601–612.
  24. Levac, D., Colquhoun, H., & O’Brien, K. K. (2010). Scoping studies: Advancing the methodology. Implementation Science, 5, 69. https://doi.org/10.1186/1748-5908-5-69
  25. Li, M., Xie, H., Liu, Y., Xia, C., Cun, X., Long, Y., Chen, X., Deng, M., Guo, R., Zhang, Z., & He, Q. (2019). Knockdown of hypoxia-inducible factor-1 alpha by tumor-targeted delivery of CRISPR/Cas9 suppresses pancreatic cancer metastasis. Journal of Controlled Release, 304, 204–215. https://doi.org/10.1016/j.jconrel.2019.05.019
  26. Locatelli, F., et al. (2024). Exagamglogene autotemcel for transfusion-dependent β-thalassemia. New England Journal of Medicine, 390(10), 819–832. https://doi.org/10.1056/NEJMoa2309673
  27. Murphy, R., Carroll, R. W., & Krebs, J. D. (2013). Pathogenesis of the metabolic syndrome: Insights from monogenic disorders. Mediators of Inflammation, 2013, Article 920214. https://doi.org/10.1155/2013/920214
  28. Nguyen, T. H., & Anegon, I. (2016). Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo: Delivery vector and immune responses are key to success. EMBO Molecular Medicine, 8(5), 473–476. https://doi.org/10.15252/emmm.201606325
  29. Pierce, E. A., et al. (2024). In vivo CRISPR-based gene editing for inherited retinal degeneration. Nature Medicine, 30(5), 501–512.
  30. Ritter, S. J., et al. (2024). CRISPR correction of ELANE mutations restores granulopoiesis in severe congenital neutropenia. Blood, 143(8), 1024–1036.
  31. Rogaev, E. I. (2018). Different pathways to neurodegeneration. Biochemistry (Moscow), 83(9), 1007–1008.https://doi.org/10.1134/S0006297918090018
  32. Ryu, N., Kim, M. A., Park, D., Lee, B., Kim, Y. R., Kim, K. H., Baek, J. I., Kim, W. J., Lee, K. Y., & Kim, U. K. (2018). Effective PEI-mediated delivery of CRISPR-Cas9 complex for targeted gene therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 14(7), 2095–2102. https://doi.org/10.1016/j.nano.2018.06.009
  33. Shariati, L., et al. (2018). CRISPR-mediated SOX6 targeting for fetal hemoglobin reactivation in β-thalassemia. Stem Cell Research & Therapy, 9(1), 1–12.
  34. Sommer, C., et al. (2019). Multiplex CRISPR engineering of human T cells for enhanced immunotherapy. Nature Biomedical Engineering, 3(8), 678–689.
  35. Subica, A. M. (2023). CRISPR in public health: The health equity implications and role of community in gene-editing research and applications. American Journal of Public Health, 113(8), 874–882. https://doi.org/10.2105/AJPH.2023.307315
  36. Swaminathan, P. I., et al. (2025). Safety and activity of allogeneic CRISPR-engineered CAR-T therapy in relapsed lymphoma. The Lancet Oncology, 26(1), 110–122.
  37. Taguchi, I., et al. (2019). Ethical attitudes toward clinical genome editing among genetic professionals. Journal of Human Genetics, 64(5), 437–445.
  38. Tricco, A. C., Lillie, E., Zarin, W., O’Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Horsley, T., Weeks, L., Hempel, S., Akl, E. A., Chang, C., McGowan, J., Stewart, L., Hartling, L., Aldcroft, A., Wilson, M. G., Garritty, C., … Straus, S. E. (2018). PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Annals of Internal Medicine, 169(7), 467–473. https://doi.org/10.7326/M18-0850
  39. Uddin, F., Rudin, C. M., & Sen, T. (2020). CRISPR gene therapy: Applications, limitations, and implications for the future. Frontiers in Oncology, 10, Article 1387. https://doi.org/10.3389/fonc.2020.01387
  40. Wiley, L., Cheek, M., LaFar, E., Ma, X., Sekowski, J., Tanguturi, N., & Iltis, A. (2025). The ethics of human embryo editing via CRISPR-Cas9 technology: A systematic review of ethical arguments, reasons, and concerns. HEC Forum, 37(2), 267–303. https://doi.org/10.1007/s10730-024-09538-1
  41. Xu, P., Tong, Y., Liu, X. Z., Wang, T. T., Cheng, L., Wang, B. Y., Lv, X., Huang, Y., & Liu, D. P. (2015). Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 mutation in β-thalassemia-derived iPSCs. Scientific Reports, 5, Article 12065. https://doi.org/10.1038/srep12065
  42. Young, J. K., Gasior, S. L., Jones, S., & Wang, L. (2015). A comprehensive review of CRISPR platform development and specificity optimization strategies. Molecular Therapy, 23(7), 1234–1245.
  43. Zabaleta, N., Barberia, M., Martin-Higueras, C., Zapata-Linares, N., Betancor, I., Rodriguez, S., Martinez-Turrillas, R., Torella, L., Vales, A., Olagüe, C., et al. (2018). CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I. Nature Communications, 9, Article 5454. https://doi.org/10.1038/s41467-018-07827-1
  44. Zhang, S., Li, M., Zeng, J., Zhou, S., Yue, F., Chen, Z., Ma, L., Wang, Y., Wang, F., & Luo, J. (2025). Somatostatin receptor-targeted polymeric nanoplatform for efficient CRISPR/Cas9 gene editing to enhance synergistic hepatocellular carcinoma therapy. Journal of Nanobiotechnology, 23, Article 127. https://doi.org/10.1186/s12951-025-03214-3
  45. Zhao, N., Wang, G., Das, A. T., & Berkhout, B. (2017). Combinatorial CRISPR-Cas9 and RNA interference attack on HIV-1 DNA and RNA can lead to cross-resistance. Antimicrobial Agents and Chemotherapy, 61(12), e01486-17. https://doi.org/10.1128/AAC.01486-17

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.